LXEO Company Profile and Key Details

NASDAQ : LXEO

Lexeo Therapeutics Common Stock

$5.09

-0.41-7.46%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Lexeo Therapeutics, Inc. Common Stock (LXEO) stock declined over -7.45%, trading at $5.09 on NASDAQ, down from the previous close of $5.50. The stock opened at $5.41, fluctuating between $5.01 and $5.47 in the recent session.

Stock Snapshot

5.5

Prev. Close

399.68M

Market Cap

5.01

Day Low

-4.54

P/E Ratio

-1.12

EPS (TTM)

N/A

Cash Flow per Share

5.41

Open

78.52M

Number of Shares

5.47

Day High

65.64%

Free Float in %

N/A

Book Value

787.39K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 15, 2026	5.41	5.47	5.01	5.09	787.39K
May 14, 2026	5.81	5.85	5.45	5.50	424.43K
May 13, 2026	5.69	6.00	5.61	5.76	1.24M
May 12, 2026	6.11	6.18	5.68	5.70	1.02M
May 11, 2026	6.00	6.43	5.93	6.12	964.98K
May 08, 2026	5.82	5.96	5.67	5.83	987.32K
May 07, 2026	6.19	6.30	5.74	5.82	571.92K
May 06, 2026	6.03	6.29	5.89	6.23	609.52K
May 05, 2026	5.88	6.03	5.74	5.96	416.49K
May 04, 2026	5.72	5.95	5.68	5.80	307.1K
Apr 30, 2026	5.70	5.84	5.65	5.70	392.58K
Apr 29, 2026	5.73	5.76	5.61	5.68	365.54K
Apr 28, 2026	5.62	5.89	5.61	5.81	427.17K
Apr 27, 2026	5.89	6.08	5.60	5.63	728.88K
Apr 23, 2026	6.31	6.36	5.94	6.01	1.07M
Apr 22, 2026	6.35	6.46	6.27	6.33	1.06M
Apr 21, 2026	6.55	6.63	6.22	6.29	763.69K
Apr 20, 2026	6.89	6.95	6.49	6.53	813.38K
Apr 17, 2026	6.81	7.02	6.73	6.91	656.81K
Apr 16, 2026	6.79	6.79	6.48	6.58	478.13K

Contact Details

New York City, 10010

United States

https://www.lexeotx.com 212 547 9879

About Company

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Stock Peers

ARGX

-22.81-2.77%

argenx SE$799.32 REGN

-14.62-2.05%

Regeneron Pharmaceuticals, Inc.$698.25 UTHR

-7.21-1.25%

United Therapeutics Corporation$568.58 MDGL

-16.2-3.00%

Madrigal Pharmaceuticals, Inc.$523.69 VRTX

-13.46-2.99%

Vertex Pharmaceuticals Incorporated$436.95 PRAX

-2.94-0.85%

Praxis Precision Medicines, Inc.$342.58 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-10.01-3.16%

Krystal Biotech, Inc.$306.29 ALNY

-6.47-2.20%

Alnylam Pharmaceuticals, Inc.$286.98 ASND

-4.99-2.03%

Ascendis Pharma A/S$240.50

Company Overview

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO) closed at $5.09 USD, losing -$0.41 (-7.45%) from the previous close of $5.50. The stock is currently mid-range between its 52-week high and low $2.51 and $10.99. With a market capitalization of about $399.68 million, Lexeo Therapeutics, Inc. Common Stock is classified as a small-cap and shows higher-than-market volatility (beta ~1.53). Key stats such as the average daily volume over the past year has been around 876.21 thousand shares, in line with its 52-week average. Headquartered in New York City, None, Lexeo Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO R. Nolan Townsend, the company employs approximately 75 people and listed since November 03, 2023. Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases.

Technical Performance

LXEO has shown weak momentum, losing -10.59% over the past week and -24.22% over the past quarter, though year-to-date performance is down -26.89%. Short-term trend indicators are mixed aligned (SMA20 0.49%, SMA50 -15.23%, SMA200 6.27%). The stock’s 14-day RSI is 45.31 (neutral), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -37.22% below its high and over 375.86% above its low. Average 10-day trading volume of 780.81 thousand shares is below the 3-month average of 894.91 thousand, indicating normal recent market interest.

Valuation Metrics

Lexeo Therapeutics, Inc. Common Stock trades at a P/E ratio of -4.73, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.79 suggesting the stock is closer to book value. The P/FCF stands at -4.07, also above market averages.

Dividend & Fair Value

Lexeo Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.03. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Lexeo Therapeutics, Inc. Common Stock generated EPS of -$2.70 over the past year. Five-year average earnings growth is -99.98%. Wall Street analysts project EPS growth of 24.04% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $9.00. The high target offers 489.39% upside. The low target suggests 76.82% downside. The mean target is $17.50. This offers 243.81% upside. Lexeo Therapeutics, Inc. Common Stock earnings surprise history is frequent misses against expectations. The quarter that ended May 11, 2026, missed forecasts by -13.79%. The prior quarter beat by -15.62%. Over the last six quarters, Apple has recorded several small beats. These include -10.34% in March 24, 2025.

Shareholding & Insider Activity

Lexeo Therapeutics, Inc. Common Stock has 54.00 million shares outstanding. The public float is 29.38 million shares, elevated short interest at 10.72% of float. This equals 5.28 million shares. The short ratio is 13.36 days. Institutional investors hold 89.82% of the float. Insiders own 0.53%. Longitude Capital Partners IV, LLC holds 2.57 million shares, Omega Fund VI, L.P. has 2.16 million shares and Townsend Richard Nolan has 340.11 thousand shares. Over the past six months, insider transactions show net selling. They sold 71.59 thousand shares across 8 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Lexeo Therapeutics Common Stock has not generated any revenue.
On valuation metrics, Lexeo Therapeutics Common Stock trades at a P/E of -4.73, P/S of 0.00 and P/B of 1.79. The current ratio is 14.16 and quick ratio is 14.16. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -2229.44 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.03, supported by a cash flow-to-debt ratio of -13.30.

Price Forecast & Outlook

Our AI price prediction model suggests that Lexeo Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.54%, with price expected at $5.27 by May 28, 2026, within a range of $4.93 to $5.60 3-Month Outlook: Projected rise of 135.95%, reaching $12.01 by August 12, 2026, with a range of $11.66 to $12.29. 1-Year Outlook: Projected gain of 4.72%, with price at $5.33 by May 14, 2027, within a range of $0.00 to $6.57.

Key Takeaways

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO) shares are down -26.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Lexeo Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -4.73. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.06, suggesting 294.11% upside. Our AI forecast model points to short-term strength (3.54% over two weeks), a medium-term rise (135.95% over three months), and a longer-term gain (4.72% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Lexeo Therapeutics, Inc. Common Stock (LXEO) stock price?

Lexeo Therapeutics, Inc. Common Stock (NASDAQ: LXEO) stock price is $5.09 in the last trading session. During the trading session, LXEO stock reached the peak price of $5.47 while $5.01 was the lowest point it dropped to. The percentage change in LXEO stock occurred in the recent session was -7.45% while the dollar amount for the price change in LXEO stock was - $0.41.

LXEO's industry and sector of operation?

The NASDAQ listed LXEO is part of Biotechnology industry that operates in the broader Healthcare sector. Lexeo Therapeutics, Inc. Common Stock designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LXEO?

No Data

How LXEO did perform over past 52-week?

LXEO's closing price is 102.71% higher than its 52-week low of $2.51 where as its distance from 52-week high of $10.99 is -53.69%.

How many employees does LXEO have?

Number of LXEO employees currently stands at 75.

Link for LXEO official website?

Official Website of LXEO is: https://www.lexeotx.com

How do I contact LXEO?

LXEO could be contacted at phone 212 547 9879 and can also be accessed through its website. LXEO operates from 345 Park Avenue South, New York City, 10010, United States.

How many shares of LXEO are traded daily?

LXEO stock volume for the day was 787.39K shares. The average number of LXEO shares traded daily for last 3 months was 876.21K.

What is the market cap of LXEO currently?

The market value of LXEO currently stands at $399.68M with its latest stock price at $5.09 and 78.52M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	75
Beta	1.8
Sales or Revenue	N/A
5Y Sales Change%	-1%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

LXEO Company Profile and Key Details

Lexeo Therapeutics Common Stock

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics